Hapoalim Reiterating Sell On MannKind (MNKD)

Hapoalim Securities is reiterating its Sell rating and $1 price target on shares of MannKind MNKD. In a note to investors, Hapoalim writes, "MannKind announced that it has met with the FDA for an End-of-Review meeting for the Afrezza program and while the FDA seems to have agreed on the protocol for the required Type 1 trial, there appears to some confusion over what would be an acceptable protocol for the Type 2 trial. MannKind stated that it now plans to complete the new Phase 3 trials in late 2012, which implies to us an early 2013 filing with the FDA. If Afrezza gets a six month review (it is possible it gets a new 10 month review), it would imply a 2H13 PDUFA date. We reiterate our SELL rating." Shares of MNKD are down 65 cents in pre-market trading to $3.75, a loss of 14.77% this morning.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorPrice TargetAnalyst RatingsBiotechnologyHapoalim SecuritiesHealth Care
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!